This study is in progress, not accepting new patients
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung Nivolumab Mocetinostat Glesatinib Sitravatinib Glesatinib and Nivolumab Sitravatinib and Nivolumab Mocetinostat and Nivolumab
Lead Scientist at UCSF
- Collin Blakely
Dr. Blakely is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Mirati Therapeutics Inc.
- Phase 2
- Study Type
- Last Updated